Navigation Links
'TF beacons' may light path to new cancer tests and drugs
Date:9/7/2011

Scientists are reporting development of a long-sought new way to detect the activity of proteins that bind to the DNA in genes, often controlling the activity of genes in ways that make cells do everything from growing normally to becoming cancerous. Their report appears in the Journal of the American Chemical Society.

Kevin Plaxco, Francesco Ricci and colleagues note that more than 10 percent of the 25,000-30,000 genes in the human body contain instructions for manufacturing these so-called DNA-binding proteins. Most of these proteins are master regulators called transcription factors (TFs). They start or stop the first step in the process in which gene's instructions are put into action. TFs bind to DNA and turn genes on or off. Understanding and measuring the activity of TFs is important because they are involved in health and disease, with many linked to cancers, for instance. With existing ways of detecting the activity of TFs being slow and cumbersome, the scientists set out to overcome that barrier.

The scientists describe development and successful tests of fluorescent sensors that they term "transcription factor beacons." The beacons signal the activity and concentration of TFs directly in biological samples by switching from a dark state to a fluorescent state upon binding to their specific TF. Using TF Beacons is simpler and works faster than current methods, and the scientists say TF beacons may have multiple uses in diagnosing cancer, searching for new cancer drugs and other areas.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers use nanoparticles as destructive beacons to zap tumors
2. Highlights of upcoming conference on aldosterone & the ENaC/Degenerin family of ion channels
3. Up from the depths: How bacteria capture carbon in the twilight zone
4. Weight loss without the hunger: Cornell scientists say eat a lighter lunch
5. The genome of mesopolyploid crop Brassica rapa sheds new light on the study of genome evolution
6. New imaging method sheds light on cell growth
7. New theory may shed light on dynamics of large-polymer liquids
8. Small molecules shed light on cancer therapies
9. Study sheds light on late phase of asthma attacks
10. Scientists highlight link between stress and appetite
11. The flight of the bumble bee: Why are they disappearing?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology: